How effective is crizotinib in treating lung adenocarcinoma?

Crizotinib, as a targeted therapy drug, plays an important role in the treatment of lung adenocarcinoma. Its efficacy is mainly reflected in patients with specific gene mutations, especially those with abnormalities in the ALK gene, ROS1 ROS1 gene or C-MET gene.

Crizotinib is particularly suitable for patients with changes in cancer genes in the body and can kill some lung adenocarcinoma cells. For lung adenocarcinoma patients with ALK gene mutations, ROS1 mutations or C-MET gene amplification, the use of crizotinib can significantly prolong the progression-free survival of patients, with a median time of more than 10 months. This means that during treatment with crizotinib, the patient's condition can be effectively controlled and the quality of life improved.

Although crizotinib may cause some side effects during treatment, such as gastrointestinal reactions (nausea, vomiting, etc.), visual abnormalities, liver function damage, etc., most patients can tolerate these side effects. Under the guidance and monitoring of a doctor, drug dosages can be adjusted in a timely manner or corresponding measures can be taken to reduce side effects, ensuring that patients can continue to receive and benefit from treatment.

Before starting crizotinib, it is critical that patients undergo genetic testing. This can help determine whether patients have genetic mutations associated with crizotinib sensitivity, thereby guiding medication decisions. Appropriate patient groups selected through genetic testing can receive crizotinib treatment more accurately, improving treatment effects and reducing unnecessary drug exposure.